niceatm
iccvam
conven
intern
workshop
review
state
scienc
human
veterinari
vaccin
potenc
safeti
test
method
identifi
opportun
advanc
new
improv
method
reduc
refin
replac
anim
use
report
address
method
strategi
identifi
workshop
particip
replac
anim
use
potenc
test
human
vaccin
vaccin
consid
highest
prioriti
futur
effort
vaccin
antigen
quantif
method
alreadi
develop
valid
vaccinescompon
requir
largest
number
anim
vaccin
requir
vivo
challeng
test
vaccin
vivo
test
highli
variabl
caus
signific
number
invalid
test
vaccin
potenc
test
identifi
highest
prioriti
replac
diphtheria
tetanu
pertussi
whole
cell
acellular
rabi
anthrax
polio
vaccin
inactiv
complex
combin
vaccin
base
dt
dtwpap
research
understand
precis
mechan
protect
afford
vaccin
identif
clinic
relev
immunolog
marker
need
facilit
success
implement
vitro
test
altern
report
also
identifi
sever
prioriti
human
vaccin
associ
research
object
necessari
success
implement
vitro
vaccin
potenc
test
altern
publish
elsevi
ltd
select
andor
peerreview
respons
nation
toxicolog
program
interag
center
evalu
altern
toxicolog
method
niceatm
vaccin
contribut
improv
anim
human
health
welfar
prevent
control
infecti
diseas
howev
test
necessari
ensur
vaccin
effect
safeti
involv
larg
number
anim
signific
pain
distress
accordingli
us
interag
coordin
committe
valid
altern
method
iccvam
us
nation
toxicolog
program
interag
center
evalu
altern
toxicolog
method
niceatm
recent
identifi
vaccin
potenc
safeti
test
one
four
highest
prioriti
iccvam
interag
committe
feder
agenc
charg
law
evalu
new
revis
altern
test
method
regulatori
applic
iccvam
member
repres
us
feder
regulatori
research
agenc
requir
use
gener
dissemin
safeti
test
data
includ
depart
agricultur
usda
regul
veterinari
vaccin
food
drug
administr
fda
regul
human
vaccin
iccvam
perman
interag
committe
nation
institut
environment
health
scienc
nieh
niceatm
niceatm
administ
iccvam
provid
scientif
oper
support
iccvamrel
activ
conduct
intern
valid
studi
promis
new
safeti
test
method
niceatm
iccvam
serv
critic
public
health
role
translat
research
advanc
bench
standard
safeti
test
method
use
regulatori
practic
prevent
diseas
injuri
promot
advanc
develop
use
scientif
valid
altern
method
human
veterinari
vaccin
test
niceatm
iccvam
organ
intern
workshop
altern
method
reduc
refin
replac
use
anim
vaccin
potenc
safeti
test
state
scienc
futur
direct
workshop
held
nation
institut
health
bethesda
maryland
septemb
organ
conjunct
european
centr
valid
altern
method
ecvam
japanes
center
valid
altern
method
jacvam
health
canada
workshop
address
state
scienc
human
veterinari
vaccin
potenc
safeti
test
particip
develop
recommend
futur
progress
three
major
area
vitro
replac
method
potenc
test
reduct
refin
method
potenc
test
reduct
refin
replac
method
vaccin
safeti
test
report
prepar
three
topic
human
vaccin
three
topic
veterinari
vaccin
report
address
method
strategi
replac
anim
use
potenc
test
human
vaccin
goal
intern
workshop
identifi
promot
implement
current
avail
accept
altern
method
reduc
refin
replac
use
anim
human
veterinari
vaccin
potenc
safeti
test
review
state
scienc
altern
method
identifi
knowledg
data
gap
need
address
identifi
priorit
research
develop
valid
effort
need
address
gap
order
advanc
altern
method
also
ensur
continu
protect
human
anim
health
workshop
organ
four
plenari
session
three
breakout
group
session
breakout
session
workshop
particip
identifi
criteria
priorit
vaccin
potenc
safeti
test
futur
altern
test
method
develop
identifi
high
prioriti
use
criteria
review
current
state
scienc
altern
method
discuss
way
promot
implement
avail
method
identifi
knowledg
data
gap
need
address
identifi
priorit
research
develop
valid
effort
need
address
gap
order
advanc
altern
method
ensur
continu
protect
human
anim
health
workshop
open
plenari
session
expert
scientist
regulatori
author
unit
state
europ
japan
canada
outlin
import
vaccin
human
anim
health
describ
nation
intern
regulatori
test
requir
human
veterinari
vaccin
author
emphas
follow
regulatori
approv
vaccin
test
requir
ensur
subsequ
product
lot
pure
safe
suffici
potent
gener
protect
immun
respons
peopl
anim
second
plenari
session
address
method
accept
method
develop
requir
use
anim
assess
potenc
vaccin
follow
breakout
session
discuss
state
scienc
recommend
futur
progress
vitro
potenc
test
human
veterinari
vaccin
workshop
recommend
advanc
use
develop
altern
method
replac
anim
potenc
test
human
vaccin
provid
paper
report
replac
anim
veterinari
vaccin
avail
elsewher
proceed
third
plenari
session
address
potenc
test
method
refin
procedur
avoid
lessen
pain
distress
incorpor
earlier
human
endpoint
use
antibodi
quantif
test
instead
challeng
test
method
approach
reduc
number
anim
requir
test
breakout
group
discuss
state
scienc
develop
recommend
futur
progress
workshop
recommend
advanc
use
develop
altern
method
reduc
refin
anim
use
potenc
test
human
vaccin
veterinari
vaccin
avail
respect
public
proceed
final
plenari
session
address
method
approach
reduc
refin
replac
anim
use
assess
safeti
serial
product
lot
human
veterinari
vaccin
breakout
group
discuss
state
scienc
develop
recommend
advanc
altern
method
vaccin
safeti
test
workshop
recommend
advanc
use
develop
altern
method
safeti
test
human
vaccin
veterinari
vaccin
avail
respect
public
proceed
human
vaccin
save
live
prevent
diseas
morbid
repres
critic
tool
success
costsav
health
intervent
exampl
us
birth
cohort
receiv
seri
seven
vaccin
protect
infecti
diseas
includ
diphtheria
tetanu
pertussi
measl
mump
rubella
polio
estim
million
diseas
episod
prematur
death
prevent
vaccin
estim
save
billion
dollar
medic
societ
cost
number
anim
use
annual
releas
human
vaccin
mani
regulatori
agenc
activ
encourag
evalu
develop
implement
novel
approach
reduc
refin
replac
use
anim
vaccin
safeti
potenc
product
releas
test
us
public
health
servic
act
certain
section
us
food
drug
cosmet
act
give
fda
author
regul
human
vaccin
section
public
health
servic
act
state
approv
biolog
licens
base
demonstr
product
safeti
puriti
potenc
assur
facil
manufactur
process
packag
meet
standard
ensur
product
releas
distribut
safe
pure
potent
regulatori
definit
safeti
puriti
potenc
detail
titl
us
code
feder
regul
test
methodolog
valid
must
includ
biolog
licens
applic
bla
safeti
potenc
test
may
perform
final
bulk
sampl
final
contain
sampl
may
consist
either
vivo
vitro
test
postlicens
chang
potenc
safeti
test
requir
supplement
licens
adequ
rational
data
support
altern
method
potenc
safeti
support
demonstr
lack
need
particular
test
safeti
current
human
vaccin
consist
live
virus
modifi
live
attenu
virus
bacteria
inactiv
kill
virus
bacteria
toxoid
chemic
inactiv
toxin
polysaccharid
gener
type
potenc
test
employ
vaccin
manufactur
includ
titrat
live
organ
vitro
occasion
vivo
vitro
assay
enzymelink
immunosorb
assay
elisa
antigen
quantif
method
vivo
method
involv
immun
small
laboratori
anim
eg
guinea
pig
rat
mice
follow
challeng
toxinvirusbacteria
titrat
immun
sera
measur
antibodi
respons
vitro
potenc
test
use
live
attenu
vaccin
commonli
use
inactiv
vaccin
center
biolog
evalu
research
cber
activ
research
program
evalu
develop
integr
novel
scientif
technolog
use
product
regul
cber
program
includ
develop
analysi
approach
reduc
refin
replac
use
anim
cber
encourag
develop
altern
method
vaccin
safeti
potenc
test
appropri
relev
support
data
test
method
valid
reduct
refin
approach
appli
serolog
vaccinationchalleng
method
use
anim
determin
potenc
human
vaccin
current
potenc
test
method
sever
human
vaccin
still
util
anim
tabl
develop
altern
assay
product
would
significantli
reduc
number
anim
use
test
benefit
anim
welfar
identifi
human
vaccin
prioriti
develop
valid
vitro
replac
test
criteria
priorit
establish
workshop
workshop
particip
agre
follow
vaccin
priorit
criteria
develop
vitro
potenc
test
vaccin
antigen
quantif
method
alreadi
develop
valid
routin
use
vaccinescompon
requir
largest
number
anim
vaccin
requir
vivo
challeng
test
vaccin
vivo
test
highli
variabl
caus
signific
number
invalid
test
vaccin
relationship
antigen
quantiti
potenc
well
understood
combin
vaccin
recogn
complex
may
make
success
replac
difficult
singlecompon
vaccin
vaccin
welldefin
understood
mode
action
known
target
vaccin
manufactur
process
well
understood
consist
base
upon
key
criteria
describ
workshop
particip
identifi
follow
vaccin
highest
prioriti
addit
research
develop
valid
effort
diphtheria
tetanu
toxoid
vaccin
whole
cell
acellular
pertussi
vaccin
rabi
vaccin
anthrax
vaccin
complex
combin
vaccin
inactiv
polio
vaccin
diphtheria
tetanu
toxoid
consid
highest
prioriti
current
potenc
test
requir
larg
number
anim
rabi
anthrax
vaccin
identifi
prioriti
test
also
requir
larg
number
anim
may
involv
signific
pain
distress
addit
vaccinechalleng
test
vaccin
requir
use
live
viru
toxin
bacteria
pose
signific
safeti
risk
laboratori
technician
current
vivo
potenc
test
inactiv
rabi
vaccin
also
known
highli
variabl
produc
signific
number
invalid
test
final
use
antigen
quantif
method
vaccin
protect
antigen
alreadi
known
consid
high
prioriti
valid
develop
shown
tabl
serolog
method
current
develop
approv
use
specif
regulatori
author
mani
highprior
vaccin
avail
refin
method
indic
therefor
aid
develop
replac
method
base
vitro
antigen
quantif
current
human
vaccin
requir
use
anim
vitro
method
develop
quantifi
presenc
protect
antigen
socal
antigen
quantif
method
base
bind
key
protect
antigen
vaccin
batch
specif
antibodi
use
vitro
immunoassay
present
time
method
repres
promis
vitro
approach
replac
anim
use
vaccin
potenc
test
import
note
howev
vitro
antigen
quantif
method
measur
antigen
quantiti
necessarili
reflect
biolog
activ
anoth
limit
method
requir
adjuv
remov
product
test
therefor
necessari
also
demonstr
process
adjuv
remov
affect
recoveri
andor
integr
antigen
could
interfer
detect
assay
date
vitro
test
success
implement
regulatori
accept
product
includ
hepat
ab
vaccin
inactiv
polio
vaccin
polysaccharid
polysaccharid
conjug
vaccin
human
papillomaviru
vaccin
tabl
recombin
hepat
b
vaccin
two
type
vitro
immunoassay
develop
altern
mous
immunogen
test
first
base
direct
determin
hepat
b
surfac
antigen
hbsag
base
neutral
hbsag
subsequ
detect
remain
antihbsag
antibodi
elisa
perhap
critic
need
valid
altern
potenc
test
area
rabi
vaccin
tradit
method
inactiv
rabi
vaccin
potenc
test
multipledilut
vaccin
challeng
test
mice
test
commonli
refer
nih
test
origin
develop
nation
institut
health
base
rel
proport
anim
protect
rabi
group
receiv
test
vaccin
compar
immun
refer
vaccin
need
altern
test
critic
tradit
potenc
test
requir
larg
number
anim
experi
unreliev
pain
distress
approxim
half
test
anim
die
develop
acut
sign
rabi
eg
convuls
paresi
paralysi
inher
variabl
assay
contribut
high
number
invalid
assay
lead
use
anim
repeat
test
potenti
exposur
laboratori
technician
biohazard
materi
test
also
import
consider
recent
year
nation
intern
regulatori
agenc
introduc
one
initi
rabi
vaccin
potenc
test
seen
signific
improv
welfar
test
anim
includ
singledilut
assay
reduc
number
dilut
therefor
anim
test
reduct
routin
use
human
endpoint
allow
earlier
studi
termin
refin
serolog
assay
obviat
need
vivo
challeng
rabi
viru
refin
antigen
quantif
method
avail
may
one
day
elimin
need
vivo
potenc
test
replac
lead
signific
reduct
use
anim
test
sever
type
vitro
elisa
procedur
rabi
vaccin
develop
past
year
take
advantag
advanc
defin
neutral
epitop
assay
would
confer
distinct
advantag
vivo
test
method
eg
anim
requir
faster
less
costli
limit
imped
develop
implement
includ
follow
univers
applic
vaccin
strain
use
combin
adjuv
correl
well
vivo
challeng
test
clear
correl
yet
demonstr
among
amount
antigen
requir
induc
protect
immun
respons
anim
amount
antigen
measur
use
altern
vitro
assay
immun
respons
human
vaccin
therefor
difficult
correl
potenc
defin
protect
anim
versu
potenc
defin
altern
method
howev
studi
target
toward
potenti
use
elisa
procedur
rabi
vaccin
potenc
test
ongo
initi
repres
critic
first
step
toward
develop
scientif
valid
altern
replac
method
potenc
test
rabi
vaccin
note
european
pharmacopoeia
issu
draft
propos
comment
use
antibodi
quantif
lot
releas
rabi
vaccin
veterinari
use
subject
productspecif
valid
identif
highestprior
vaccin
replac
potenc
assay
develop
knowledg
data
gap
previous
prevent
use
nonanim
potenc
assay
must
address
thorough
understand
pathogenesi
infecti
diseas
associ
protect
mechan
necessari
accur
identifi
specif
antigen
key
epitop
respons
elicit
protect
immun
respons
clinic
relev
antigenepitop
identifi
studi
requir
fulli
understand
role
protect
antigen
vaccin
may
affect
vaccin
manufactur
process
eg
epitop
modif
due
detoxif
absorpt
adjuv
process
may
alter
vaccin
present
immun
system
process
target
speci
studi
conduct
determin
structur
stabil
antigen
immunolog
marker
ultim
identifi
measur
immun
respons
target
speci
vaccin
antigen
mechan
protect
well
understood
antigen
well
character
case
diphtheria
tetanu
antigen
despit
complex
detoxif
product
process
involv
manufactur
toxoid
vaccin
method
avail
vitro
quantif
antigen
final
product
howev
amount
antigen
detect
use
vitro
method
biolog
activ
vivo
potenc
may
depend
addit
factor
exampl
certain
combin
vaccin
contain
tetanu
toxoid
activ
ingredi
hib
polysaccharid
conjug
tetanu
toxoid
eg
dtwp
hibtt
experiment
dtapipv
hibvaccin
tetanu
potenc
measur
use
vivo
method
increas
rel
potenc
vaccin
contain
hibtt
compon
due
presenc
carrier
protein
case
amount
tetanu
toxoid
detect
vitro
bind
assay
may
differ
vitro
assay
detect
conjug
tetanu
toxoid
circumst
may
addit
challeng
address
replac
vivo
test
vitro
detect
method
avail
select
anim
diseas
model
facilit
identif
immunolog
marker
aid
develop
vitro
test
exampl
vaccin
contain
recombin
papillomaviru
viruslik
particl
vlp
use
control
diseas
cow
dog
rabbit
success
provid
basi
subsequ
licensur
bival
quadraval
human
papilloma
viru
hpv
vaccin
control
cervic
cancer
human
readi
access
relev
inform
play
key
role
develop
valid
subsequ
implement
vitro
vaccin
potenc
test
method
ideal
manufactur
regulatori
author
frequent
interact
share
inform
order
avoid
duplic
effort
defin
procedur
use
valid
altern
vitro
test
howev
proprietari
issu
may
limit
dissemin
inform
outsid
stakehold
increas
engag
academ
research
could
provid
mean
inform
public
variou
vehicl
journal
public
workshop
scientificprofession
societi
meet
strategi
develop
altern
replac
method
must
base
stepbystep
approach
ideal
definit
potenc
assay
vivo
vitro
develop
licens
elimin
need
parallel
vivo
test
licens
complex
compar
protocol
final
clear
need
differenti
test
limit
measur
amount
antigen
addit
test
demonstr
manufactur
consist
singl
test
assess
antigen
quantiti
unlik
provid
requir
inform
chang
structur
properti
product
affect
efficaci
may
detect
test
therefor
addit
prioriti
would
determin
abil
vitro
antigen
quantif
test
predict
product
molecular
stabil
andor
biolog
activ
signific
time
resourc
requir
prioriti
vaccin
complex
associ
move
vivo
test
method
one
use
anim
signific
cost
associ
research
develop
valid
vitro
vaccin
potenc
test
method
therefor
workshop
particip
strongli
encourag
earli
frequent
interact
regul
throughout
process
maxim
likelihood
final
design
accept
regulatori
author
avoid
unnecessari
delay
workshop
particip
agre
broader
access
relev
inform
describ
success
implement
altern
potenc
test
method
would
obviou
impact
expand
use
accept
exampl
open
onlin
access
unit
state
pharmacopeia
usp
european
pharmacopoeia
ph
eur
monograph
would
greatli
facilit
dissemin
method
procedur
implement
use
regul
variou
region
manufactur
also
encourag
frequent
consult
relev
regulatori
author
regard
plan
studi
design
best
incorpor
altern
method
vaccin
potenc
test
ie
productspecif
valid
workshop
particip
recogn
need
harmon
vaccin
develop
phase
note
guidelin
would
standard
approach
roadmap
transit
vivo
vitro
test
would
help
collabor
interlaboratori
studi
involv
nation
control
author
supran
organ
european
director
qualiti
medicin
edqm
ph
eur
could
accomplish
workshop
particip
recogn
signific
cost
lack
avail
fund
associ
addit
research
develop
valid
effort
vitro
vaccin
potenc
test
method
primari
barrier
progress
specif
agre
concern
associ
rabi
vaccin
antigen
quantif
method
need
address
includ
increas
avail
refer
standard
antisera
variou
rabi
strain
well
maintain
consist
sourc
antisera
prefer
set
nonproprietari
monoclon
antibodi
workshop
particip
identifi
follow
issu
would
aid
facilit
broader
accept
altern
method
establish
readili
avail
andor
nonproprietari
refer
standard
share
resourc
includ
key
reagent
assay
procedur
educ
outreach
bioethic
train
conduct
assay
intern
harmon
requir
accept
test
method
signific
differ
exist
human
veterinari
vaccin
product
formul
notabl
presenc
complex
adjuv
adjuv
combin
veterinari
vaccin
extrapol
result
vitro
method
develop
veterinari
vaccin
similar
human
vaccin
often
possibl
exampl
human
influenza
vaccin
often
adjuv
veterinari
influenza
vaccin
eg
avian
swine
may
contain
miner
oil
complex
adjuv
use
adjuv
may
also
result
significantli
lower
antigen
content
veterinari
vaccin
compar
present
nonadjuv
human
vaccin
veterinari
vaccin
often
well
character
correspond
human
vaccin
typic
compos
complex
mixtur
includ
antigen
deriv
whole
cell
cell
lysat
cell
cultur
supernat
variabl
could
influenc
safeti
potenc
vaccin
product
tabl
provid
list
veterinari
vaccin
antigen
quantif
method
accept
use
regulatori
author
take
account
signific
differ
human
veterinari
vaccin
workshop
particip
discuss
way
extrapol
altern
potenc
test
result
veterinari
human
vaccin
increas
interact
commun
global
regulatori
agenc
research
institut
vaccin
manufactur
recogn
critic
first
step
process
one
suggest
develop
interag
task
forc
deal
specif
issu
relev
human
veterinari
medicin
exampl
increas
complex
adjuv
certain
veterinari
vaccin
result
better
understand
adjuvantantigen
interact
may
use
human
vaccin
manufactur
addit
adjuv
consid
approv
product
convers
antigen
quantif
method
current
avail
human
rabi
vaccin
inprocess
control
technic
guidelin
may
use
veterinari
rabi
vaccin
manufactur
workshop
particip
agre
need
global
harmon
could
accomplish
conven
meet
workshop
variou
regulatori
agenc
intern
research
organ
discuss
altern
vitro
vaccin
potenc
test
strategi
develop
implement
onlin
worldwid
databas
avail
altern
method
view
potenti
signific
advanc
workshop
particip
also
recogn
import
standard
lotreleas
criteria
encourag
mutual
recognit
test
result
among
regulatori
author
would
avoid
duplic
test
result
anim
use
extend
time
product
releas
public
particip
also
recogn
need
stepwis
advanc
specif
vaccin
priorit
administr
procedur
reduct
frequenc
offici
control
test
may
preced
technic
strategi
base
refin
replac
altern
incent
regulatori
author
encourag
implement
new
valid
approach
potenc
test
human
vaccin
also
view
import
consider
final
consid
critic
regul
commun
requir
qualiti
control
product
system
allow
develop
new
product
without
need
vivo
test
first
intern
workshop
held
unit
state
focus
reduct
refin
replac
anim
use
safeti
potenc
releas
test
human
veterinari
vaccin
key
accomplish
workshop
bring
togeth
expert
industri
academia
govern
area
potenc
safeti
test
human
anim
vaccin
sever
recent
symposia
sought
scienc
appli
use
anim
qualiti
control
biolog
symposia
address
variou
aspect
promot
facilit
use
nonanim
method
qualiti
control
either
human
veterinari
biolog
well
increas
understand
implement
consist
approach
manufactur
human
veterinari
biolog
sever
workshop
conven
past
sever
year
dedic
find
new
way
advanc
develop
implement
altern
method
qualiti
control
human
veterinari
biolog
workshop
highlight
need
basic
scientif
research
well
productspecif
valid
effort
advanc
develop
valid
implement
altern
method
replac
anim
use
potenc
test
human
vaccin
specif
recommend
consid
necessari
address
scientif
knowledg
gap
exist
understand
diseas
process
andor
productspecif
inform
relat
vaccin
function
strong
agreement
among
workshop
particip
thorough
indepth
understand
precis
mechan
protect
afford
vaccin
target
popul
key
first
step
move
vivo
vitro
potenc
test
recur
theme
surfac
discuss
includ
need
open
access
method
inform
pharmacopoei
monograph
increas
share
inform
among
regul
manufactur
scientif
commun
intern
harmon
requir
test
method
specif
eg
ich
r
develop
valid
potenc
assay
recognit
regulatori
author
encourag
use
approach
variou
mean
need
wide
avail
valid
refer
standard
antisera
reagent
although
specif
detail
recommend
workshopsymposium
differ
gener
theme
need
specif
scientif
research
need
intern
harmon
regul
specif
need
share
inform
respons
regul
encourag
use
altern
method
need
valid
reagent
evid
output
workshopsymposium
build
reaffirm
import
conclus
recommend
advanc
outcom
workshop
advanc
altern
method
vaccin
potenc
test
reduc
refin
replac
use
anim
test
maintain
promot
scientif
qualiti
protect
human
health
anim
health
environ
